35.Angulo MA, Castro-Magana M, Lamerson M, Arguello R, Accacha S, Khan A. Final adult height in children with Prader-Willi syndrome with and without human growth hormone treatment. Am J Med Genet A. 2007;143A:1456-61.
36.Carrel AL, Myers SE, Whitman BY, Eickhoff J, Allen DB. Long-term growth hormone therapy changes the natural history of body composition and motor function in children with prader-willi syndrome. J Clin Endocrinol Metab. 2010;95:1131-6.
37.Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, Troeman ZC, van Alfen-van der Velden AA, Otten BJ, et al. Beneficial effects of growth hormone treatment on cognition in children with PraderWilli syndrome: a randomized controlled trial and longitudinal study. J Clin Endocrinol Metab. 2012;97:2307-14.
38.Moore SJ, Green JS, Fan Y, Bhogal AK, Dicks E, Fernandez BA, et al. Clinical and genetic epidemiology of Bardet-Biedl syndrome in Newfoundland: a 22-year prospective, population-based, cohort study. Am J Med Genet A. 2005;132A:352-60.
39.Ben-Salem S, Begum MA, Ali BR, Al-Gazali L. A Novel Aberrant Splice Site Mutation in RAB23 Leads to an Eight Nucleotide Deletion in the mRNA and Is Responsible for Carpenter Syndrome in a Consanguineous Emirati Family. Mol Syndromol. 2013;3:255-61.
40.Tarhan E, Oğuz H, Safak MA, Samim E. The carpenter syndrome phenotype. Int J Pediatr Otorhinolaryngol. 2004;68:353-7. [OpenAIRE]
Powered by OpenAIRE Research Graph